03/09/2026
Hope for families living with LGMD ๐
Very encouraging early results from the ATA-200 clinical trial for LGMD R5 (gamma sarcoglycanopathy) were presented during the MDA Clinical and Scientific Conference, bringing renewed hope to families affected by this rare neuromuscular disease.
๐ฌ Key findings include
โข >90% SGCG expression in muscle fibers at 6 months
โข Sustained reductions in CPK and transaminases at 9 months
โข Encouraging functional improvements in ambulatory patients
โข No serious adverse events reported in the four treated children
Progress in rare diseases is the result of a collective effort with patients, families, researchers, and scientists working together toward better treatment options.
For families living with sarcoglycanopathy, every step forward in research brings renewed hope.
For more information, read the full press release
https://urls.fr/eL0ZLn
๐